Company Overview
Snapshot
Founded in July 2017 by Daniella Givon, Raanan Margalit, and Nadav Shraibom, DUN T1 operates with 1–10 employees. The company has secured funding across one round from one investor, totaling $45K. In December 2019, DUN T1 received equity crowdfunding from Fundit.
Business overview
DUN T1 is an early-stage research and development company focused on creating an orally administered drug for type 1 diabetes. The company's core technology centers on a novel, patented natural ingredient designed for proactive treatment and early diagnosis. DUN T1 operates within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals and Drugs Discovery & Development markets, with a focus on patients and pharmaceutical companies.
Log in to access full profile ›Company Intelligence Q&A
- What is DUN T1's primary focus?
- DUN T1 is an early-stage R&D company dedicated to developing an orally administered drug for type 1 diabetes, aiming for a proactive approach to treatment and early diagnosis.
- When was DUN T1 founded and by whom?
- DUN T1 was founded in July 2017 by Daniella Givon, Raanan Margalit, and Nadav Shraibom.
- What is the status of DUN T1's drug development?
- DUN T1 is currently in the R&D product stage, focusing on developing its novel natural ingredient for type 1 diabetes treatment.
- Which sector does DUN T1 operate in?
- DUN T1 operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.
- How many employees does DUN T1 have?
- DUN T1 operates with 1–10 employees.